Protocol 1
Hyperbaric oxygen therapy
Breathing pure oxygen under pressure to support tissue repair, oxygenation and recovery from inflammation.
Global Health Challenges / Lyme Disease
Infectious disease
Lyme Disease
The most common tick-borne disease in the Northern Hemisphere, and one that often escapes timely diagnosis. We are looking for investors and partners to change how Lyme is detected, treated and managed.
What is inside the platformLyme 2026 snapshotUpdated Q3 2026
67Companies
71Investors
132Clinical trials
109Clinics
Lyme diagnostics market$3.09B in 2026
▲ $4.53B by 20322025 in focus118.5 per 100kMassachusetts, 8,619 probable cases in 2025
Highest in Europe230 per 100kEstonia, latest reported year
~476,000cases a year in the US
132,000+reported cases a year in Europe
14.5%global seroprevalence
22–36%early test sensitivity
Global perspective
Lyme is far more widespread than case counts show
An estimated 14.5% of people worldwide carry antibodies from a past Borrelia infection. Lyme can leave lasting inflammation and immune effects, and a growing body of research links chronic infection to the onset or progression of age-related conditions.
Lyme seroprevalence in the general population, Europe
Share of people with antibodies, studies using two-tier testing
National studies range from 2.7% in Norway to 20% in Finland.
1.17 billionpeople worldwide estimated to have been exposed to Borrelia
230 per 100,000reported incidence in Estonia in 2024, the highest in the world, followed by the Netherlands and Slovenia
RisingTick habitats are spreading north and to higher altitudes as climates warm
Lyme incidence mapOpen the interactive visualisation
Seasonality
When Lyme strikes
Lyme cases follow the life cycle of ticks. Most infections happen in late spring and summer, when small nymph ticks are active and people spend more time outdoors, with a smaller rise in autumn from adult ticks. Knowing the season helps time prevention campaigns, testing and clinic capacity.
SpringTicks become active as temperatures rise
Summer peakMost new cases, driven by nymph ticks
AutumnSecond, smaller rise from adult ticks
WinterLowest risk, but not zero on mild days
Peak seasonJun–Julover half of all cases
Share of US Lyme cases by month of onset, 2010–2019
Lyme seasonalityOpen the interactive visualisation
Lyme market in charts
A growing market for treatment and diagnostics
Rising case numbers, investment from major healthcare companies and more precise diagnostic methods, including spectroscopy-based tests, are driving steady growth in both segments.
$4.1B → $7.8BGlobal Lyme market, 2024 to 2032
6.3%Annual growth in diagnostics, $2.8B to $4.5B
7%Annual growth in treatment, $1.4B to $2.3B
Lyme market sizeOpen the interactive visualisation
Clinical research
Where Lyme clinical trials happen
The United States hosts the largest share of Lyme trials, while European countries together account for about half. Since 2019 the field has averaged around 10 new studies a year, driven by diagnostics and prevention research.
Share of Lyme clinical trials by country
As of 2025
~10new Lyme clinical studies per year on average since 2019, led by diagnostics and prevention research
Leading research organisations
- PfizerUSA
- ValnevaFrance / Austria
- NIAIDUSA
- University Medical Centre LjubljanaSlovenia
- University Hospital StrasbourgFrance
- Sørlandet HospitalNorway
- Tarsus PharmaceuticalsUSA
- Research Foundation for Mental HygieneUSA
Source: Longevity Industry Analytics.
The challenge
Where Lyme care still falls short
Late diagnosis, persistent symptoms and fragmented data still hold back patient care, research and investment.
22–36%test sensitivity in early infection
Diagnosis comes too late
Antibody tests miss most cases in the first weeks, when treatment works best. Many patients never notice the tick bite or the rash.
Monthsof symptoms for some patients after treatment
Persistent symptoms
Some patients still struggle with fatigue, pain and cognitive problems after standard antibiotics, often alongside co-infections.
New regionsas tick habitats expand
A moving map
Warmer climates and changing land use are pushing ticks into new areas, putting populations with little awareness at risk.
Fragmenteddata across countries and sectors
No single view of the field
Surveillance, trials, companies and funding are tracked in separate systems, making gaps and opportunities hard to see.
Patient pathway
The Lyme patient journey
Explore each stage of the journey, from exposure and early signs to testing, treatment and long-term care. Click a stage to see the AI-based diagnostic, treatment and management options behind it.
Lyme patient journeyOpen the interactive visualisation
Solutions for Lyme
Personalised longevity-medicine protocols
Many patients still struggle with symptoms after standard antibiotics. Drawing on more than a decade of analytical work, consortium clinics combine cutting-edge and natural therapies from mitochondrial, space, restorative and functional medicine, tailored to each patient’s co-infections and complicating factors.
Assess co-infections and complicating factorsBuild a personalised protocolMonitor recovery and adjust
Protocol 2
Intermittent hypoxia–hyperoxia training
Alternating low- and high-oxygen breathing to train mitochondrial resilience and energy metabolism.
Protocol 3
Plasmapheresis
Filtering blood plasma to remove inflammatory and immune factors in selected patients.
Protocol 4
Keto and carnivore diets
Low-carbohydrate nutrition protocols to reduce inflammation and support metabolic health.
These protocols complement, and do not replace, standard antibiotic treatment. Evidence for their use in Lyme disease is still developing, and treatment is decided case by case by the clinical team.
Lyme Fighters app
Track symptoms, learn and connect, all in one app
Lyme Fighters Tribe is a project backed by the Biogerontology Research Foundation, improving the lives of people affected by Lyme disease through technology and community support.
- Daily symptom trackingCheck in every day and follow symptom severity over time.
- Health insights and trendsSee monthly changes and how your health is developing.
- Health checks and assessmentsLyme questionnaires and assessments to share with your doctor.
- Guides, stories and free e-bookLyme Stories, practical guides and the free e-book Undoing Lyme.
- Deep Breath and My NutritionBreathing sessions and nutrition support built into the app.
- Chat and communityTalk to other Lyme Fighters and support the Oxi Wave Foundation.
Join the Lyme FightersAvailable on iPhone and Android for patients, families and caregivers
Read more
Lyme analytics and reports, Q3 2026
Our latest analysis of the Lyme landscape, from a short teaser to the full landscape overview.
Lyme Disease Intelligence Platform
We are building one hub for the market and business intelligence of the Lyme field, with benchmarking, competitive and SWOT analysis across companies, technologies, trials and investors.
- 67 companies in diagnostics, treatments and prevention
- 132 clinical trials by stage, sponsor and region
- 71 investors and their Lyme portfolios
- 109 clinics specialising in Lyme care, with hotspot and burden maps
Lyme Disease IntelligenceOverviewCompaniesInvestorsTrialsDiagnostics
Region: GlobalAsset type: AllStage: AllYears: 2019–2026Search…
Companies67Diagnostics, therapies, clinics
Clinical trials132Mapped worldwide
Investors71VC, pharma, public
Clinics109Lyme specialists
Incidence and research hotspots
Highest reported incidence, 2024
| Country | Cases per 100k | Level |
|---|---|---|
| Estonia | 230 | Very high |
| Netherlands | 147 | Very high |
| Slovenia | 119 | Very high |
Work with us on Lyme disease
Invest, partner on research, analytics or pilot programmes, or represent the Lyme challenge in your community.
Sources: CDC Lyme disease estimates; European surveillance and industry reports (2026); Dong et al., global seroprevalence meta-analysis, BMJ Global Health (2022); systematic review of Lyme borreliosis seroprevalence in Europe (2005–2020); Lyme Disease Biobank evaluation of two-tiered testing; Longevity Industry Analytics market and clinical trial data.